Abstract | BACKGROUND: METHODS: We retrospectively analyzed the clinical course (median follow-up, 5.9 years) of 54 young children with SDNS (43 boys; age < 10 years) who had undergone 12-week CPM therapy. The patients were classified into two groups: group A, undergoing MZR therapy for > 12 months for maintaining remission after CPM therapy (N = 36), and group B, undergoing CPM monotherapy (N = 18). RESULTS: For 2 years after CPM therapy, 21 of the 36 group A patients were in sustained remission, whereas only 4 of the 18 group B patients had maintained remission (58% vs. 22%, p < 0.05). Furthermore, the rate of regression to SDNS after CPM was significantly lower in group A than in group B (6% vs. 39%, p < 0.05). At the last follow-up (mean age, 10.9 years), 27 of the 36 group A patients (75%) had not received any steroid-sparing agent after the treatment regimen. CONCLUSIONS: Single daily high-dose MZR therapy after CPM therapy may have positive outcomes in young children with SDNS in the long term.
|
Authors | Akira Mizutani, Shuichiro Fujinaga, Koji Sakuraya, Daishi Hirano, Toshiaki Shimizu |
Journal | Clinical and experimental nephrology
(Clin Exp Nephrol)
Vol. 23
Issue 2
Pg. 244-250
(Feb 2019)
ISSN: 1437-7799 [Electronic] Japan |
PMID | 30121800
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Immunosuppressive Agents
- Ribonucleosides
- Steroids
- mizoribine
- Cyclophosphamide
|
Topics |
- Adolescent
- Age of Onset
- Child
- Child, Preschool
- Cyclophosphamide
(administration & dosage, adverse effects)
- Drug Administration Schedule
- Female
- Humans
- Immunosuppressive Agents
(administration & dosage, adverse effects)
- Male
- Nephrotic Syndrome
(diagnosis, drug therapy, immunology)
- Recurrence
- Remission Induction
- Retrospective Studies
- Ribonucleosides
(administration & dosage, adverse effects)
- Steroids
(administration & dosage, adverse effects)
- Time Factors
- Treatment Outcome
|